Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Document Type
Journal Article
Publication Date
2-26-2020
Journal
Scientific Reports
Volume
10
Issue
1
Inclusive Pages
3470
DOI
10.1038/s41598-020-60409-4
APA Citation
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M., Palmer, E., Austin, P. T., Chisholm, S., Roche, K., Yu, A., Li, J., Zhu, W., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2020). Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.. Scientific Reports, 10 (1). http://dx.doi.org/10.1038/s41598-020-60409-4
Peer Reviewed
1
Open Access
1
